| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Fibrinogen Binding Inhibitor Peptide targets the activated glycoprotein (GP) IIb/IIIa receptor on platelets. It acts as a specific binding site for the ligand of activated GP IIb/IIIa, playing a role in platelet aggregation. By inhibiting the binding of fibrinogen, fibronectin, and von Willebrand factor to thrombin- or ADP-stimulated platelets, it prevents platelet aggregation.
|
|---|---|
| ln Vitro |
At the site of vascular injury, platelets attach to exposed collagen, causing glycoprotein (GP) IIb/IIIa, which is found on the platelet membrane, to transition from an inactive to an active state. Fibrinogen mediates platelet aggregation in the blood by connecting neighboring platelets via GPIIb/IIIa in a manner that is activation-dependent. The dodecapeptide HHLGGAKQAGDV (H12) is a particular binding site for GPIIb/IIIa ligand activation, and it corresponds to the carboxyl-terminal region (γ400–411) of the fibrinogen γ chain [1].
In vitro, Fibrinogen Binding Inhibitor Peptide is an effective inhibitor of fibrinogen binding to platelets. It specifically targets the binding site for activated GP IIb/IIIa. It is used to study the mechanisms of platelet aggregation and adhesion. Its activity is confirmed in platelet aggregation assays where it inhibits aggregation induced by ADP or thrombin. |
| ln Vivo |
In vivo, Fibrinogen Binding Inhibitor Peptide is not used as a therapeutic agent. It is used as a research tool to study thrombosis and cardiovascular disease mechanisms. By inhibiting platelet aggregation, it can serve as a model for studying anti-thrombotic strategies. It is a valuable probe for dissecting the mechanisms of fibrinogen-mediated cellular adhesion and aggregation.
|
| Enzyme Assay |
The in vitro platelet aggregation assay is the primary method for evaluating the activity of Fibrinogen Binding Inhibitor Peptide. Platelet-rich plasma (PRP) is incubated with the peptide and then stimulated with an agonist such as ADP or thrombin. Platelet aggregation is measured using a platelet aggregometer, which monitors the increase in light transmission. The inhibition of aggregation is calculated.
|
| Cell Assay |
In vitro cell culture studies for Fibrinogen Binding Inhibitor Peptide are not typical, as its target is platelets, which are not cultured. However, its effects on platelet function can be studied in whole blood or PRP. Its binding to GP IIb/IIIa can be studied using flow cytometry with fluorescently labeled antibodies or the peptide itself.
|
| Animal Protocol |
In vivo animal experiments for Fibrinogen Binding Inhibitor Peptide are not extensively documented. However, its anti-thrombotic effects could be studied in animal models of thrombosis, such as the ferric chloride-induced arterial thrombosis model or the pulmonary embolism model. The peptide would be administered, and parameters such as time to occlusion or survival would be measured.
|
| ADME/Pharmacokinetics |
Fibrinogen Binding Inhibitor Peptide is a lyophilized powder with a molecular weight of 1189.28 g/mol. It is soluble in water and aqueous buffers. It is typically stored as a powder at -20°C for long-term stability. Its stability is maintained under recommended storage conditions. It is a synthetic peptide.
|
| Toxicity/Toxicokinetics |
Toxicological data for Fibrinogen Binding Inhibitor Peptide are limited, as it is a research compound. It is not intended for human use. Comprehensive toxicity studies have not been reported. Standard safety precautions for handling peptides should be followed.
|
| References | |
| Additional Infomation |
Fibrinogen Binding Inhibitor Peptide is a research compound with no clinical approval. It is a valuable tool for studying platelet biology, thrombosis, and hemostasis. It is used to investigate the role of the GP IIb/IIIa receptor in platelet aggregation and adhesion. It is also used to screen for potential anti-thrombotic agents and to study the mechanisms of cardiovascular disease.
|
| Molecular Formula |
C50H80N18O16
|
|---|---|
| Molecular Weight |
1189.2812
|
| Exact Mass |
1188.6
|
| CAS # |
89105-94-2
|
| PubChem CID |
9941719
|
| Appearance |
White to off-white solid powder
|
| Density |
1.342g/cm3
|
| Boiling Point |
1809.886ºC at 760 mmHg
|
| Flash Point |
1048.381ºC
|
| LogP |
-9.7
|
| Hydrogen Bond Donor Count |
18
|
| Hydrogen Bond Acceptor Count |
20
|
| Rotatable Bond Count |
39
|
| Heavy Atom Count |
84
|
| Complexity |
2310
|
| Defined Atom Stereocenter Count |
9
|
| SMILES |
[C@@H](NC(=O)[C@@H](N)CC1NC=NC=1)(C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(=O)O)C(=O)N[C@H](C(=O)O)C(C)C)CC1NC=NC=1
|
| InChi Key |
STSKWZSBFZRSGP-GYDGUXFESA-N
|
| InChi Code |
InChI=1S/C50H80N18O16/c1-24(2)13-33(67-48(81)34(15-29-18-55-23-60-29)66-44(77)30(52)14-28-17-54-22-59-28)45(78)58-19-37(70)56-20-38(71)61-27(6)43(76)64-31(9-7-8-12-51)47(80)65-32(10-11-36(53)69)46(79)62-26(5)42(75)57-21-39(72)63-35(16-40(73)74)49(82)68-41(25(3)4)50(83)84/h17-18,22-27,30-35,41H,7-16,19-21,51-52H2,1-6H3,(H2,53,69)(H,54,59)(H,55,60)(H,56,70)(H,57,75)(H,58,78)(H,61,71)(H,62,79)(H,63,72)(H,64,76)(H,65,80)(H,66,77)(H,67,81)(H,68,82)(H,73,74)(H,83,84)/t26-,27-,30-,31-,32-,33-,34-,35-,41-/m0/s1
|
| Chemical Name |
(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-6-amino-2-[[(2S)-2-[[2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-(1H-imidazol-5-yl)propanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]acetyl]amino]propanoyl]amino]hexanoyl]amino]-5-oxopentanoyl]amino]propanoyl]amino]acetyl]amino]-3-carboxypropanoyl]amino]-3-methylbutanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~84.08 mM)
H2O : ~100 mg/mL (~84.08 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (2.10 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (2.10 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (2.10 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.8408 mL | 4.2042 mL | 8.4084 mL | |
| 5 mM | 0.1682 mL | 0.8408 mL | 1.6817 mL | |
| 10 mM | 0.0841 mL | 0.4204 mL | 0.8408 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
